226 related articles for article (PubMed ID: 15291358)
1. Nuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells.
Ozpolat B; Tari AM; Mehta K; Lopez-Berestein G
Leuk Lymphoma; 2004 May; 45(5):979-85. PubMed ID: 15291358
[TBL] [Abstract][Full Text] [Related]
2. all-trans-Retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia.
Ozpolat B; Mehta K; Tari AM; Lopez-Berestein G
Am J Hematol; 2002 May; 70(1):39-47. PubMed ID: 11994980
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer progression in MCF10A series of cell lines is associated with alterations in retinoic acid and retinoid X receptors and with differential response to retinoids.
Peng X; Yun D; Christov K
Int J Oncol; 2004 Oct; 25(4):961-71. PubMed ID: 15375546
[TBL] [Abstract][Full Text] [Related]
4. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid.
Delia D; Aiello A; Lombardi L; Pelicci PG; Grignani F; Grignani F; Formelli F; Menard S; Costa A; Veronesi U
Cancer Res; 1993 Dec; 53(24):6036-41. PubMed ID: 8261419
[TBL] [Abstract][Full Text] [Related]
5. Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines.
Kazmi SM; Plante RK; Visconti V; Lau CY
Cancer Res; 1996 Mar; 56(5):1056-62. PubMed ID: 8640761
[TBL] [Abstract][Full Text] [Related]
6. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma.
Sheikh MS; Shao ZM; Li XS; Ordonez JV; Conley BA; Wu S; Dawson MI; Han QX; Chao WR; Quick T
Carcinogenesis; 1995 Oct; 16(10):2477-86. PubMed ID: 7586155
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR).
Webber MM; Bello-DeOcampo D; Quader S; Deocampo ND; Metcalfe WS; Sharp RM
Clin Exp Metastasis; 1999 May; 17(3):255-63. PubMed ID: 10432011
[TBL] [Abstract][Full Text] [Related]
8. Comparing the effect of ATRA, 4-HPR, and CD437 in bladder cancer cells.
Zou C; Zhou J; Qian L; Feugang JM; Liu J; Wang X; Wu S; Ding H; Zou C; Liebert M; Grossman HB
Front Biosci; 2006 Sep; 11():2007-16. PubMed ID: 16720286
[TBL] [Abstract][Full Text] [Related]
9. Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1.
Villani MG; Appierto V; Cavadini E; Valsecchi M; Sonnino S; Curley RW; Formelli F
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6265-75. PubMed ID: 15448016
[TBL] [Abstract][Full Text] [Related]
10. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
Sabichi AL; Xu H; Fischer S; Zou C; Yang X; Steele VE; Kelloff GJ; Lotan R; Clifford JL
Clin Cancer Res; 2003 Oct; 9(12):4606-13. PubMed ID: 14555536
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.
Xu H; Cheepala S; McCauley E; Coombes K; Xiao L; Fischer SM; Clifford JL
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):969-79. PubMed ID: 16467112
[TBL] [Abstract][Full Text] [Related]
12. 4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RARgamma independent pathway.
Kitareewan S; Spinella MJ; Allopenna J; Reczek PR; Dmitrovsky E
Oncogene; 1999 Oct; 18(42):5747-55. PubMed ID: 10523855
[TBL] [Abstract][Full Text] [Related]
13. Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide.
Sabichi AL; Hendricks DT; Bober MA; Birrer MJ
J Natl Cancer Inst; 1998 Apr; 90(8):597-605. PubMed ID: 9554442
[TBL] [Abstract][Full Text] [Related]
14. RARalpha is a regulatory factor for Am-80-induced cell growth inhibition of hematologic malignant cells.
Jimi S; Mashima K; Matsumoto T; Hara S; Suzumiya J; Tamura K
Int J Oncol; 2007 Aug; 31(2):397-404. PubMed ID: 17611697
[TBL] [Abstract][Full Text] [Related]
15. Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha.
Drach J; McQueen T; Engel H; Andreeff M; Robertson KA; Collins SJ; Malavasi F; Mehta K
Cancer Res; 1994 Apr; 54(7):1746-52. PubMed ID: 7511050
[TBL] [Abstract][Full Text] [Related]
16. Differentiation-independent retinoid induction of folate receptor type beta, a potential tumor target in myeloid leukemia.
Wang H; Zheng X; Behm FG; Ratnam M
Blood; 2000 Nov; 96(10):3529-36. PubMed ID: 11071651
[TBL] [Abstract][Full Text] [Related]
17. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2.
Delia D; Aiello A; Formelli F; Fontanella E; Costa A; Miyashita T; Reed JC; Pierotti MA
Blood; 1995 Jan; 85(2):359-67. PubMed ID: 7811993
[TBL] [Abstract][Full Text] [Related]
18. N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).
Faderl S; Lotan R; Kantarjian HM; Harris D; Van Q; Estrov Z
Leuk Res; 2003 Mar; 27(3):259-66. PubMed ID: 12537979
[TBL] [Abstract][Full Text] [Related]
19. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line.
Appierto V; Cavadini E; Pergolizzi R; Cleris L; Lotan R; Canevari S; Formelli F
Br J Cancer; 2001 Jun; 84(11):1528-34. PubMed ID: 11384104
[TBL] [Abstract][Full Text] [Related]
20. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl)retinamide] sufficient for cancer therapy?
Ohlmann CH; Jung C; Jaques G
Int J Cancer; 2002 Aug; 100(5):520-6. PubMed ID: 12124800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
